The majority of epidermal growth factor receptor (EGFR) mutations (85–90%) are exon 19
deletions and L858R point mutations of exon 21, characterized by high sensitivity to EGFR …

Simple Summary Epidermal growth factor receptor (EGFR) mutations occur in a significant
number of lung cancer patients. Treatment outcomes in this subset of patients has greatly …

Background FLAURA, the prospective trial of osimertinib as a first-line therapy compared
with first-generation epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKIs) …

Mutations in the epidermal growth factor receptor (EGFR) gene are the most common
targetable genomic drivers of non-small cell lung cancer (NSCLC), occurring in …

Objectives Epidermal growth factor receptor (EGFR) exon 20 insertions comprise 4–10% of
EGFR mutations in non-small cell lung cancer (NSCLC) and are associated with primary …

The efficacy of epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKI) in
patients with non-small cell lung cancer (NSCLC) is related to EGFR mutations. Although the …

Background Clinical guidelines advise osimertinib as preferred first line treatment for
advanced epidermal growth factor receptor (EGFR) mutated non-small cell lung cancer …

Background The strong association between smoking history and the presence of epidermal
growth factor receptor (EGFR) mutations has been proven in non–small-cell lung cancer …

Osimertinib, a third-generation EGFR TKI, is the standard therapy for previously untreated
EGFR-mutated non-small cell lung cancer patients following the landmark FLAURA study …

Background EGFR mutation status is closely related to the efficacy of EGFR-TKIs in
advanced non-small cell lung cancer (NSCLC). EGFR-TKIs have become the standard first …